MDxHealth: Presentation of New Data for MDxHealth's Prostate Cancer Diagnostic Tests at AUA 2019 Annual Meeting
03 Mai 2019 - 07:01AM
PRESS RELEASE Moderated posters feature clinical
validations of SelectMDx and ConfirmMDx
IRVINE, CA, and HERSTAL, BELGIUM - MAY 3, 2019 -
MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative
molecular diagnostics company, today announced that positive data
demonstrating the clinical value of ConfirmMDx and SelectMDx for
prostate cancer will be presented in two moderated posters at the
2019 American Urological Association (AUA) Annual Meeting, May 1-6
in Chicago.
Data highlights
- Clinical utility study demonstrates that ConfirmMDx had a
significant positive impact on repeat prostate biopsy
decision-making in a US community urology practice setting.
- In a 1,955-patient clinical validation study, SelectMDx
demonstrated a high sensitivity and negative predictive value for
the detection of clinically significant prostate cancer.
Details are as follows:
Poster: MP24-02: Clinical Utility of
ConfirmMDx For Prostate Cancer in a Community Urology Practice
Date: Saturday, May 4, 2019Time: 07:00 - 09:00 CDTThe
abstract and authors are available to view here.
Poster: MP24-04: A 2-Gene MRNA Urine Test
For Detection of High-Grade Prostate Cancer Prior to Initial
Prostate Biopsy Date: Saturday, May 4, 2019Time:
07:00 - 09:00 CDTThe abstract and authors are available to view
here.
The AUA annual meeting takes place at the
McCormick Place convention center in Chicago, and more information
is available on the meeting website.
For more information:
Consilium Strategic
CommunicationsAmber Fennell, Chris Welsh, David Daley, Marieke
Vermeersch UK: +44 20 3709 5701
mdxhealth@consilium-comms.com |
About MDxHealth
MDxHealth is a multinational healthcare company
that provides actionable molecular diagnostic information to
personalize the diagnosis and treatment of cancer. The company's
tests are based on proprietary genetic, epigenetic (methylation)
and other molecular technologies and assist physicians with the
diagnosis of urologic cancers, prognosis of recurrence risk, and
prediction of therapeutic response. The Company's European
headquarters are in Herstal, Belgium, with laboratory operations in
Nijmegen, The Netherlands, and US headquarters and laboratory
operations based in Irvine, California. For more information, visit
mdxhealth.com.
DisclaimerThis press release contains forward-looking
statements and estimates with respect to the anticipated future
performance of MDxHealth and the market in which it operates. Such
statements and estimates are based on assumptions and assessments
of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual
events are difficult to predict, may depend upon factors that are
beyond the company's control, and may turn out to be materially
different. MDxHealth expressly disclaims any obligation to update
any such forward-looking statements in this release to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based unless required by law or regulation. This press
release does not constitute an offer or invitation for the sale or
purchase of securities or assets of MDxHealth in any jurisdiction.
No securities of MDxHealth may be offered or sold within the United
States without registration under the U.S. Securities Act of 1933,
as amended, or in compliance with an exemption therefrom, and in
accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth,
ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are
trademarks or registered trademarks of MDxHealth SA. All other
trademarks and service marks are the property of their respective
owners.
MDxHealth (EU:MDXH)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
MDxHealth (EU:MDXH)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024